Application of real options analysis for pharmaceutical R&D project valuation—Empirical results from a survey

Real options analysis was often recommended as an emerging valuation technique for high-risk investment projects. Former inter-sectoral surveys have drawn an ambivalent picture of real options usage in general. In addition, there is a lack of sector-specific investigations. In the following article the results of an in-depth analysis of collected empirical data regarding the application of this new tool in the pharmaceutical sector is presented by capturing the internal view from the pharmaceutical companies themselves and the external view from the health care departments of financial service firms. R&D stage specific modi of application, reasons for reluctance in the employment of real options and their assumed future prospects are elucidated.

[1]  Rita Gunther McGrath,et al.  Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms , 2004 .

[2]  James E. Smith,et al.  Valuing Risky Projects: Option Pricing Theory and Decision Analysis , 1995 .

[3]  John M. Charnes,et al.  Real-Options Valuation for a Biotechnology Company , 2000 .

[4]  S. Ross,et al.  Option pricing: A simplified approach☆ , 1979 .

[5]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[6]  R. Vollrath.  Die Berücksichtigung von Handlungsflexibilität bei Investitionsentscheidungen — Eine empirische Untersuchung , 2001 .

[7]  N. A. Nichols.  Scientific management at Merck: An interview with CFO Judy Lewent , 1994 .

[8]  Hariolf Grupp,et al.  The Derivation of R&D Return Indicators within a Real Options Framework , 2003 .

[9]  F. Black,et al.  The Pricing of Options and Corporate Liabilities , 1973, Journal of Political Economy.

[10]  T. Copeland.  Real Options: A Practitioner's Guide , 2001 .

[11]  T. Dublin,et al.  Research policy , 2021, The Routledge Handbook of Gender and EU Politics.

[12]  Barbara M. Bolten,et al.  Trends in development cycles , 2002, Nature Reviews Drug Discovery.

[13]  P. Tufano,et al.  A real-world way to manage real options. , 2004, Harvard business review.

[14]  James L. Gilbert,et al.  Rebuilding Big Pharma ’ s Business Model , 2022 .

[15]  Stewart C. Myers,et al.  Finance Theory and Financial Strategy , 1984 .

[16]  R. Geske.  THE VALUATION OF COMPOUND OPTIONS , 1979 .

[17]  S. H. Ang,et al.  Dealing with Uncertainties in the Biotechnology Industry: The Use of Real Options Reasoning , 2001 .

[18]  Danny Cassimon,et al.  The valuation of a NDA using a 6-fold compound option , 2004 .

[19]  Young Hoon Kwak,et al.  In search of innovative techniques to evaluate pharmaceutical R&D projects , 2003 .

[20]  H. Grabowski,et al.  Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade , 1997 .

[21]  Realize Hidden Value Through Timely Portfolio Decisions , 2008 .

[22]  J. Busby,et al.  Real Options In Practice: An Exploratory Survey Of How Finance Officers Deal With Flexibility In Capital Appraisal , 1997 .

[23]  Sydney Howell,et al.  Laboratory Evidence on How Managers Intuitively Value Real Growth Options , 1997 .

[24]  R. C. Merton,et al.  Theory of Rational Option Pricing , 2015, World Scientific Reference on Contingent Claims Analysis in Corporate Finance.

[25]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.